Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Conference News AHA 2016

PCI at Centers Without Surgical Backup ‘Probably OK,’ Nationwide Data Suggests

Yael L. Maxwell

November 16, 2016

AEGIS-I Trial: The Safety and Tolerability of CSL112

Presentation AHA 2016

The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Human ApoA-I, After Acute Myocardial Infarction: The ApoA-I Event reducingG in Ischemic Syndromes I Trial (AEGIS-I)

Presenter: Michael Gibson

November 15, 2016

News Conference News AHA 2016

No CV Safety Differences for COX-2 Inhibitor vs Other NSAIDs in PRECISION

Shelley Wood

November 13, 2016

News Conference News AHA 2015

Knowing Genetic Risk for MI Motivates Patients, Physicians to Get Cholesterol Levels Lower

Yael L. Maxwell

November 08, 2015

News Conference News AHA 2014

Regional STEMI Care Systems Improve Treatment Times

Yael L. Maxwell

November 18, 2014

News Conference News AHA 2014

AVOIDing Oxygen in Suspected STEMI Tied to Smaller Infarcts, Less Recurrent MI

Yael L. Maxwell

November 18, 2014

News Conference News AHA 2014

Mitral Repair at the Time of CABG Provides No Mortality, QoL Benefit at 1 Year

Yael L. Maxwell

November 17, 2014

News Conference News AHA 2014

Extending Clopidogrel Past 1 Year Improves Outcomes in DES, But Not BMS Patients

Yael L. Maxwell

November 16, 2014

News Conference News AHA 2014

Long-Term Better than Short-Term Prasugrel After PES Stenting

November 15, 2014

News Conference News AHA 2013

STREAM: Pre-hospital Fibrinolysis Strategy as Safe as Primary PCI at 1 Year in STEMI

Yael L. Maxwell

November 18, 2013

News Conference News AHA 2012

Cell Therapy Trials Show Mixed Results at AHA 2012

November 05, 2012

Presentation AHA 2012

Rivaroxaban Use is Associated with Reduced Risk of Myocardial Infarction- Insights from a Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials

Presenter: Saurav Chatterjee

November 04, 2012

News Conference News AHA 2012

EMPIRE: Exenatide Cardioprotective in STEMI Patients Receiving DES

Jason Kahn

November 04, 2012

News Conference News AHA 2012

FREEDOM: CABG Superior to PCI in Diabetic Patients with Multivessel Disease

November 04, 2012

News Conference News

MI FREEE: Free Post-MI Drugs Reduce Events, Costs

November 15, 2011

News Conference News

No LateTIME Benefit for Cell Therapy After Primary PCI

November 14, 2011

News Conference News

ISAR-REACT 4: Bivalirudin Reduces Major Bleeding in NSTEMI Patients

November 13, 2011

News Conference News

AIDA STEMI: No Advantage for Intracoronary vs. Intravenous Abciximab

November 13, 2011

Advertisement

PCI at Centers Without Surgical Backup ‘Probably OK,’ Nationwide Data Suggests

The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Human ApoA-I, After Acute Myocardial Infarction: The ApoA-I Event reducingG in Ischemic Syndromes I Trial (AEGIS-I)

No CV Safety Differences for COX-2 Inhibitor vs Other NSAIDs in PRECISION

Knowing Genetic Risk for MI Motivates Patients, Physicians to Get Cholesterol Levels Lower

Regional STEMI Care Systems Improve Treatment Times

AVOIDing Oxygen in Suspected STEMI Tied to Smaller Infarcts, Less Recurrent MI

Mitral Repair at the Time of CABG Provides No Mortality, QoL Benefit at 1 Year

Extending Clopidogrel Past 1 Year Improves Outcomes in DES, But Not BMS Patients

Long-Term Better than Short-Term Prasugrel After PES Stenting

STREAM: Pre-hospital Fibrinolysis Strategy as Safe as Primary PCI at 1 Year in STEMI

Cell Therapy Trials Show Mixed Results at AHA 2012

Rivaroxaban Use is Associated with Reduced Risk of Myocardial Infarction- Insights from a Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials

EMPIRE: Exenatide Cardioprotective in STEMI Patients Receiving DES

FREEDOM: CABG Superior to PCI in Diabetic Patients with Multivessel Disease

MI FREEE: Free Post-MI Drugs Reduce Events, Costs

No LateTIME Benefit for Cell Therapy After Primary PCI

ISAR-REACT 4: Bivalirudin Reduces Major Bleeding in NSTEMI Patients

AIDA STEMI: No Advantage for Intracoronary vs. Intravenous Abciximab

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content